

Detection and characterisation of previously unreported molecular mobility of pharmaceutically important molecules by Thermally Stimulated Current (TSC) Spectroscopy

Milan D. Antonijević



Overview of presentation

- **Introduction to Thermally Stimulated Current Spectroscopy (TSC)**
- **Examples**
 - amorphous,
 - polymorphs,
 - co-crystals
- **Conclusions**









“ 1 in 5000
drugs makes
it from the
lab to FDA
approval ”

TSC is a general term applied to the measurement of current generated by temperature-activated relaxation of molecular dipoles in response to the application of a static electric field



- 1936, Frei and Grotzinger
- electrets, ionic crystals
- waxes, resins
- ceramics, plastic
- small organic molecules








- **SDC** (spontaneous depolarisation current)
heating/cooling without an electrical field
- **TSPC** (thermally stimulated polarisation current)
heating/cooling utilising an applied static electrical field throughout
- **TSDC** (thermally stimulated depolarisation current)
after the sample has been subjected to polarisation via a static electrical field
- **TW** (thermal windowing) uses a series of discrete temperature polarisation windows to experimentally deconvolute the global relaxation process into elementary relaxation spectra





$$J(T) = \frac{P(T_p)}{\tau_0} \exp\left(-\frac{E}{kT}\right) \exp\left[-\frac{1}{q\tau_0} \int_{T_0}^T \exp\left(-\frac{E}{kT'}\right) dT'\right]$$

$$\tau(T) = P(T) / J(T)$$


$$\tau(T) = P(T) / J(T)$$

Arrhenius equation

$$\tau_i(T) = \tau_{oi} \exp\left(\frac{E_{ai}}{kT}\right)$$


Eyring equation

$$\tau_i(T) = \frac{h}{kT} \exp\left(\frac{\Delta G_i}{kT}\right) = \frac{h}{kT} \exp\left(-\frac{\Delta S_i}{k}\right) \exp\left(\frac{\Delta H_i}{kT}\right)$$



Pharmaceutical Applications

- **Amorphous materials**
- **Polymorphs**
- **Batch-to-batch control**
- **Co-crystals**




Global glass
relaxation process


Different relaxation
modes contributing
to overall process



Defining E_a - (TW)



T_p (°C)	T_{max} (°C)	E_a (kJ/mol)	ΔH^\ddagger (kJ/mol)
12	35	90	87
14	37	93	90
16	38	104	101
18	39	112	109
20	41	126	123
22	42	135	132
24	43	145	142
26	43	157	154
28	44	171	169
30	45	190	188
32	45	208	205
34	46	225	222
36	46	246	244
38	47	259	257
40	48	273	270
42	50	298	295



$$\text{Fragility Index } (m) = \frac{1}{2.303} \left[1 \frac{E_a(T_g)}{RT_g} \right]$$

	Integration window (K)	T _{max} (K)	E _a (kJmol ⁻¹)	m
TSDC (T _p = 303 K)	20	314.4 (0.1)	138.8 (1.0)	23.1 (1.0)
	10	314.4 (0.1)	178.3 (1.8)	29.6 (1.9)
	5	314.4 (0.1)	232.3 (1.0)	38.6 (1.0)
TSDC (T _p = 313 K)	20	314.3 (0.1)	139.8 (1.5)	23.2 (1.5)
	10	314.3 (0.1)	180.2 (1.2)	30.0 (1.2)
	5	314.3 (0.1)	244.4 (2.3)	40.6 (2.3)
TSDC (T _p = 323 K)	20	314.5 (0.1)	141.2 (1.5)	23.4 (1.5)
	10	314.5 (0.1)	183.6 (2.5)	30.5 (2.0)
	5	314.5 (0.1)	251.5 (1.4)	41.8 (1.4)

$$m = \frac{1}{2.303} \left[\frac{E_a(T_g)}{RT_g} \right]$$

Integration window 2 K

	T _m (K)	E _a (kJmol ⁻¹)	τ (s)	m
TSDC (T _p = 303 K)	314.4 (0.1)	376.0 (3.3)	59.3 (9.0)	62.4 (3.3)
TSDC (T _p = 313 K)	314.3 (0.1)	388.3 (4.0)	54.8 (8.0)	64.5 (4.0)
TSDC (T _p = 323 K)	314.5 (0.1)	385.8 (3.2)	51.4 (7.4)	64.1 (3.2)

Pharmaceutical Applications

- Amorphous materials
- **Polymorphs**
- Batch-to-batch control
- Co-crystals


Exists in two polymorphic forms:

Form I, unstable at room T, Trigonal


Form II, stable at room T, Monoclinic

Transition point: $141 \pm 2^\circ\text{C}$


Melting Point: $236 - 243^\circ\text{C}$ (British Pharmacopoeia)



Form I



Form II




α -process 139° C Form II only - *polymorphic transition*

γ -process -8° C Forms I and II - *orientation of side group*

β_1 -process 91° C Form II


β_2 -process 107° C Form I - *orientation/mobility of sub-unit*




Form I - negative peak at -8°C and 112°C



Form II - negative peak at 52°C

TSDC





SDC






Pharmaceutical Applications

- Amorphous materials
- Polymorphs
- **Batch-to-batch control**
- Co-crystals






Pharmaceutical Applications

- Amorphous materials
- Polymorphs
- Batch-to-batch control
- **Co-crystals**

- 1:1 molar ratio co-crystal (CC) of salicylic acid (SA) and benzamide (BA)
- 1:1 molar ratio physical mixture (PM)




Primary transitions:


BA = 128°C

SA = 159°C

CC = 119°C

PM = 110°C



 T_c :

CC-A = 125°C

CC-B = 119°C

PM = 110°C

Detection and characterisation of amorphous materials

Characterisation (Kinetics) of polymorphic transitions and co-crystal systems

Detection of beta and gama relaxation processes

Links between secondary (beta and gama) and primary relaxation

Batch to batch variations

PhD students:

Samuel Owusu-Ware

Anthony Cherry

Colleagues:

Prof. Babur Chowdhry

Prof. Stephen Leharne



